TY - JOUR
T1 - Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial
AU - van Nunen, Lokien
AU - Zimmermann, F.M. (Frederik)
AU - Tonino, P.A.L. (Pim)
AU - Barbato, E. (Emanuele)
AU - Baumbach, A. (Andreas)
AU - Engstrøm, T. (Thomas)
AU - Klauss, V. (Volker)
AU - MacCarthy, P.A. (Philip)
AU - Manoharan, G. (Ganesh)
AU - Oldroyd, Keith G.
AU - Ver Lee, P.N. (Peter)
AU - van 't Veer, Marcel
AU - Fearon, W.F. (William)
AU - Bruyne, de, B. (Bernard)
AU - Pijls, Nico
PY - 2015/11/7
Y1 - 2015/11/7
N2 - Summary Background In the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study, fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) improved outcome compared with angiography-guided PCI for up to 2 years of follow-up. The aim in this study was to investigate whether the favourable clinical outcome with the FFR-guided PCI in the FAME study persisted over a 5-year follow-up. Methods The FAME study was a multicentre trial done in Belgium, Denmark, Germany, the Netherlands, Sweden, the UK, and the USA. Patients (aged ???18 years) with multivessel coronary artery disease were randomly assigned to undergo angiography-guided PCI or FFR-guided PCI. Before randomisation, stenoses requiring PCI were identified on the angiogram. Patients allocated to angiography-guided PCI had revascularisation of all identified stenoses. Patients allocated to FFR-guided PCI had FFR measurements of all stenotic arteries and PCI was done only if FFR was 0??80 or less. No one was masked to treatment assignment. The primary endpoint was major adverse cardiac events at 1 year, and the data for the 5-year follow-up are reported here. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00267774. Findings After 5 years, major adverse cardiac events occurred in 31% of patients (154 of 496) in the angiography-guided group versus 28% (143 of 509 patients) in the FFR-guided group (relative risk 0??91, 95% CI 0??75-1??10; p=0??31). The number of stents placed per patient was significantly higher in the angiography-guided group than in the FFR-guided group (mean 2??7 [SD 1??2] vs 1??9 [1??3], p
AB - Summary Background In the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study, fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) improved outcome compared with angiography-guided PCI for up to 2 years of follow-up. The aim in this study was to investigate whether the favourable clinical outcome with the FFR-guided PCI in the FAME study persisted over a 5-year follow-up. Methods The FAME study was a multicentre trial done in Belgium, Denmark, Germany, the Netherlands, Sweden, the UK, and the USA. Patients (aged ???18 years) with multivessel coronary artery disease were randomly assigned to undergo angiography-guided PCI or FFR-guided PCI. Before randomisation, stenoses requiring PCI were identified on the angiogram. Patients allocated to angiography-guided PCI had revascularisation of all identified stenoses. Patients allocated to FFR-guided PCI had FFR measurements of all stenotic arteries and PCI was done only if FFR was 0??80 or less. No one was masked to treatment assignment. The primary endpoint was major adverse cardiac events at 1 year, and the data for the 5-year follow-up are reported here. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00267774. Findings After 5 years, major adverse cardiac events occurred in 31% of patients (154 of 496) in the angiography-guided group versus 28% (143 of 509 patients) in the FFR-guided group (relative risk 0??91, 95% CI 0??75-1??10; p=0??31). The number of stents placed per patient was significantly higher in the angiography-guided group than in the FFR-guided group (mean 2??7 [SD 1??2] vs 1??9 [1??3], p
U2 - 10.1016/S0140-6736(15)00057-4
DO - 10.1016/S0140-6736(15)00057-4
M3 - Article
SN - 0140-6736
VL - 386
SP - 1853
EP - 1860
JO - The Lancet
JF - The Lancet
IS - 10006
ER -